Search

Your search keyword '"ROCHIGNEUX, Philippe"' showing total 162 results
Start Over Author "ROCHIGNEUX, Philippe"
162 results on '"ROCHIGNEUX, Philippe"'

1. A French Multicenter Real-Life Study on the Biological and Clinical Parameters Associated With Response to Immune Checkpoint Inhibitors (ICIs) in Second-Line Treatment of Advanced Urothelial Carcinoma: Impact of Antibiotics Administration at the Time of ICIs Initiation

Author

Grassi, Pierre, Hilgers, Werner, Boissier, Romain, Bertucci, Alexandre, Bruyat, Damien, Duffaud, Florence, Enoch, Faustine, Rochigneux, Philippe, Mancini, Julien, and Deville, Jean-Laurent

Published
2025
Full Text
View/download PDF

2. Immune checkpoint inhibitor induced thyroid dysfunction is a frequent event post-treatment in NSCLC

Author

Zhou, Nanruoyi, Velez, Maria A, Bachrach, Benjamin, Gukasyan, Jaklin, Fares, Charlene M, Cummings, Amy L, Lind-Lebuffe, Jackson P, Akingbemi, Wisdom O, Li, Debory Y, Brodrick, Paige M, Yessuf, Nawal M, Rettinger, Sarah, Grogan, Tristan, Rochigneux, Philippe, Goldman, Jonathan W, Garon, Edward B, and Lisberg, Aaron

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Immunology, Women's Health, Cancer, Lung Cancer, Lung, Clinical Research, Immunotherapy, 6.1 Pharmaceuticals, Good Health and Well Being, Carcinoma, Non-Small-Cell Lung, Humans, Immune Checkpoint Inhibitors, Lung Neoplasms, Retrospective Studies, Thyroid Gland, Non-small cell lung cancer, Immune related adverse events, Thyroid dysfunction, Immune checkpoint inhibitor, Anti-PD-(L)1 therapy, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis
Abstract

IntroductionThyroid dysfunction is the most frequent endocrine immune related adverse event (irAE) in non-small cell lung cancer (NSCLC), typically arising 3-6 months into immune checkpoint inhibitor (ICI) therapy, but arising after ICI cessation, in some cases. Due to limited post-treatment adverse event reporting requirements on ICI trials, the incidence of ICI-induced thyroid dysfunction arising after therapy is unclear. We investigated ICI-induced thyroid dysfunction in a cohort of 294 NSCLC patients, with a specific focus on the post-treatment setting.MethodsRetrospective analysis of ICI-induced thyroid dysfunction (clinically acted upon or laboratory only) was performed in 294 UCLA NSCLC patients treated 2012-2018. Clinically acted upon thyroid dysfunction was defined as thyroid diagnosis documentation and/or thyroid medication administration. Laboratory only dysfunction was defined as abnormal thyroid labs in the absence of clinical action. Timing of thyroid dysfunction relative to ICI treatment and thyroid monitoring patterns were also assessed.Results82% (241/294) of ICI treated NSCLC patients had thyroid labs during treatment. Of these 241 patients, 13% (31/241) had clinically acted upon thyroid dysfunction prior to, 8% (18/241) during, and 4% (9/241) after ICI. Most patients, 66% (159/241), did not have thyroid labs after ICI, but in the 53 patients with labs and no prior clinical dysfunction, 17% (9/53) developed clinical dysfunction after ICI. In these 9 patients, median time from ICI initiation to dysfunction was 253 days. Two patients with post-treatment laboratory only dysfunction were observed.ConclusionsICI-induced thyroid dysfunction arising post-treatment appears more common than previously appreciated, warranting additional evaluation.

Published
2021

3. RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion

Author

Aldea, Mihaela, Marinello, Arianna, Duruisseaux, Michael, Zrafi, Wael, Conci, Nicole, Massa, Giacomo, Metro, Giulio, Monnet, Isabelle, Gomez Iranzo, Patricia, Tabbo, Fabrizio, Bria, Emilio, Guisier, Florian, Vasseur, Damien, Lindsay, Colin R., Ponce-Aix, Santiago, Cousin, Sophie, Citarella, Fabrizio, Fallet, Vincent, Minatta, Jose Nicolas, Eisert, Anna, de Saint Basile, Hortense, Audigier-Valette, Clarisse, Mezquita, Laura, Calles, Antonio, Mountzios, Giannis, Tagliamento, Marco, Remon Masip, Jordi, Raimbourg, Judith, Terrisse, Safae, Russo, Alessandro, Cortinovis, Diego, Rochigneux, Philippe, Pinato, David James, Cortellini, Alessio, Leonce, Camille, Gazzah, Anas, Ghigna, Maria-Rosa, Ferrara, Roberto, Dall’Olio, Filippo Gustavo, Passiglia, Francesco, Ludovini, Vienna, Barlesi, Fabrice, Felip, Enriqueta, Planchard, David, and Besse, Benjamin

Published
2023
Full Text
View/download PDF

4. A Transcriptomic-Based Tool to Predict Gemcitabine Sensitivity in Advanced Pancreatic Adenocarcinoma

Author

Bigonnet, Martin, Bongrain, Claire, Lermite, Emilie, Pessaux, Patrick, Giannone, Fabio, Chenard, Marie-Pierre, Michalak, Sophie, Nicolle, Rémy, Rubis, Marion, Poizat, Flora, Giovannini, Marc, Caillol, Fabrice, Rochigneux, Philippe, Fraunhoffer, Nicolas, Chanez, Brice, Teyssedou, Carlos, Iovanna, Juan L., Mitry, Emmanuel, and Dusetti, Nelson J.

Published
2023
Full Text
View/download PDF

5. Immunotherapy in MSI/dMMR tumors in the perioperative setting: The IMHOTEP trial

Author

Coutzac, Clélia, Bibeau, Frederic, Ben Abdelghani, Meher, Aparicio, Thomas, Cohen, Romain, Coquan, Elodie, Dubreuil, Olivier, Evesque, Ludovic, Ghiringhelli, François, Kim, Stefano, Lesourd, Samuel, Neuzillet, Cindy, Phelip, Jean-Marc, Piessen, Guillaume, Rochigneux, Philippe, Samalin, Emmanuelle, Soularue, Emilie, Touchefeu, Yann, Tougeron, David, Zaanan, Aziz, and de la Fouchardière, Christelle

Published
2022
Full Text
View/download PDF

6. High-dimensional mass cytometry analysis of NK cell alterations in AML identifies a subgroup with adverse clinical outcome

Author

Chretien, Anne-Sophie, Devillier, Raynier, Granjeaud, Samuel, Cordier, Charlotte, Demerle, Clemence, Salem, Nassim, Wlosik, Julia, Orlanducci, Florence, Gorvel, Laurent, Fattori, Stephane, Hospital, Marie-Anne, Pakradouni, Jihane, Gregori, Emilie, Paul, Magali, Rochigneux, Philippe, Pagliardini, Thomas, Morey, Mathieu, Fauriat, Cyril, Dulphy, Nicolas, Toubert, Antoine, Luche, Herve, Malissen, Marie, Blaise, Didier, Nunès, Jacques A., Vey, Norbert, and Olive, Daniel

Published
2021

8. Table S3 from CD25high Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer

Author

Fattori, Stéphane, primary, Le Roy, Aude, primary, Houacine, Jemila, primary, Robert, Lucie, primary, Abes, Riad, primary, Gorvel, Laurent, primary, Granjeaud, Samuel, primary, Rouvière, Marie-Sarah, primary, Ben Amara, Amira, primary, Boucherit, Nicolas, primary, Tarpin, Carole, primary, Pakradouni, Jihane, primary, Charafe-Jauffret, Emmanuelle, primary, Houvenaeghel, Gilles, primary, Lambaudie, Eric, primary, Bertucci, François, primary, Rochigneux, Philippe, primary, Gonçalves, Anthony, primary, Foussat, Arnaud, primary, Chrétien, Anne-Sophie, primary, and Olive, Daniel, primary

Published
2023
Full Text
View/download PDF

9. Supplementary_Materials_and_Methods_Figures_and_Figure_legends from CD25high Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer

Author

Fattori, Stéphane, primary, Le Roy, Aude, primary, Houacine, Jemila, primary, Robert, Lucie, primary, Abes, Riad, primary, Gorvel, Laurent, primary, Granjeaud, Samuel, primary, Rouvière, Marie-Sarah, primary, Ben Amara, Amira, primary, Boucherit, Nicolas, primary, Tarpin, Carole, primary, Pakradouni, Jihane, primary, Charafe-Jauffret, Emmanuelle, primary, Houvenaeghel, Gilles, primary, Lambaudie, Eric, primary, Bertucci, François, primary, Rochigneux, Philippe, primary, Gonçalves, Anthony, primary, Foussat, Arnaud, primary, Chrétien, Anne-Sophie, primary, and Olive, Daniel, primary

Published
2023
Full Text
View/download PDF

10. Data from CD25high Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer

Author

Fattori, Stéphane, primary, Le Roy, Aude, primary, Houacine, Jemila, primary, Robert, Lucie, primary, Abes, Riad, primary, Gorvel, Laurent, primary, Granjeaud, Samuel, primary, Rouvière, Marie-Sarah, primary, Ben Amara, Amira, primary, Boucherit, Nicolas, primary, Tarpin, Carole, primary, Pakradouni, Jihane, primary, Charafe-Jauffret, Emmanuelle, primary, Houvenaeghel, Gilles, primary, Lambaudie, Eric, primary, Bertucci, François, primary, Rochigneux, Philippe, primary, Gonçalves, Anthony, primary, Foussat, Arnaud, primary, Chrétien, Anne-Sophie, primary, and Olive, Daniel, primary

Published
2023
Full Text
View/download PDF

11. File_S1 from CD25high Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer

Author

Fattori, Stéphane, primary, Le Roy, Aude, primary, Houacine, Jemila, primary, Robert, Lucie, primary, Abes, Riad, primary, Gorvel, Laurent, primary, Granjeaud, Samuel, primary, Rouvière, Marie-Sarah, primary, Ben Amara, Amira, primary, Boucherit, Nicolas, primary, Tarpin, Carole, primary, Pakradouni, Jihane, primary, Charafe-Jauffret, Emmanuelle, primary, Houvenaeghel, Gilles, primary, Lambaudie, Eric, primary, Bertucci, François, primary, Rochigneux, Philippe, primary, Gonçalves, Anthony, primary, Foussat, Arnaud, primary, Chrétien, Anne-Sophie, primary, and Olive, Daniel, primary

Published
2023
Full Text
View/download PDF

12. Dysthyroidism during immune checkpoint inhibitors is associated with improved overall survival in adult cancers: data mining of 1385 electronic patient records

Author

Beaufils, Mathilde, primary, Amodru, Vincent, additional, Tejeda, Manuel, additional, Boher, Jean Marie, additional, Zemmour, Christophe, additional, Chanez, Brice, additional, Chrétien, Anne Sophie, additional, Gorvel, Laurent, additional, Gravis, Gwenaelle, additional, Bruyat, Damien, additional, Mari, Roxane, additional, Madroszyk, Anne, additional, Cuny, Thomas, additional, Gonçalves, Anthony, additional, Lisberg, Aaron E, additional, Olive, Daniel, additional, Tassy, Louis, additional, Castinetti, Frederic, additional, and Rochigneux, Philippe, additional

Published
2023
Full Text
View/download PDF

15. Facial palsy after administration of immune checkpoint inhibitors: case report, literature review and clinical care management.

Author

Mezni, Essia, Corazza, Giovanni, Mari, Roxane, Coze, Stephanie, Charrier, Nathalie, Chanez, Brice, Chretien, Anne Sophie, and Rochigneux, Philippe

Subjects
IMMUNE checkpoint inhibitors, LITERATURE reviews, CLINICAL medicine, DRUG side effects, PERIPHERAL nervous system, FACIAL paralysis
Abstract

Neurological immune-related adverse events (irAEs) due to immune checkpoint inhibitors (ICI) are rare complications of immunotherapy, particularly dreadful for patients and clinical teams. Indeed, neurological irAEs are potentially severe and their diagnosis require prompt recognition and treatment. Additionally, the spectrum of neurological irAEs is broad, affecting either neuromuscular junction, peripheral or central nervous system. Here, we described the case of a 55-year man with metastatic melanoma, facing a brutal right peripheral cerebral palsy after his third ipilimumab/nivolumab infusion. After the case presentation, we reviewed the literature about this rare complication of immunotherapy, and described its diagnosis work-up and clinical management. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. CD25high Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer

Author

Fattori, Stéphane, primary, Le Roy, Aude, additional, Houacine, Jemila, additional, Robert, Lucie, additional, Abes, Riad, additional, Gorvel, Laurent, additional, Granjeaud, Samuel, additional, Rouvière, Marie-Sarah, additional, Ben Amara, Amira, additional, Boucherit, Nicolas, additional, Tarpin, Carole, additional, Pakradouni, Jihane, additional, Charafe-Jauffret, Emmanuelle, additional, Houvenaeghel, Gilles, additional, Lambaudie, Eric, additional, Bertucci, François, additional, Rochigneux, Philippe, additional, Gonçalves, Anthony, additional, Foussat, Arnaud, additional, Chrétien, Anne-Sophie, additional, and Olive, Daniel, additional

Published
2023
Full Text
View/download PDF

17. Abstract 3239: Selective depletion of regulatory T cells by ALD2510, a novel IL-2-sparing anti-CD25 antibody, synergizes with PD-1 blockade in breast and gynecologic cancers

Author

FATTORI, Stéphane, primary, Roy, Aude Le, additional, Houacine, Jemila, additional, Robert, Lucie, additional, Abes, Riad, additional, Gorvel, Laurent, additional, Granjeaud, Samuel, additional, Rouvière, Marie-Sarah, additional, Amara, Amira Ben, additional, Boucherit, Nicolas, additional, Tarpin, Carole, additional, Pakradouni, Jihane, additional, Charafe-Jauffret, Emmanuelle, additional, Barrou, Julien, additional, Houvenaeghel, Gilles, additional, Lambaudie, Eric, additional, Bertucci, François, additional, Rochigneux, Philippe, additional, Gonçalves, Anthony, additional, Foussat, Arnaud, additional, Chrétien, Anne-Sophie, additional, and Olive, Daniel, additional

Published
2023
Full Text
View/download PDF

18. A Transcriptomic-Based Tool to Predict Gemcitabine Sensitivity in Advanced Pancreatic Adenocarcinoma

Author

Fraunhoffer, Nicolas, primary, Chanez, Brice, additional, Teyssedou, Carlos, additional, Iovanna, Juan L., additional, Mitry, Emmanuel, additional, Dusetti, Nelson J., additional, Bigonnet, Martin, additional, Bongrain, Claire, additional, Lermite, Emilie, additional, Pessaux, Patrick, additional, Giannone, Fabio, additional, Chenard, Marie-Pierre, additional, Michalak, Sophie, additional, Nicolle, Rémy, additional, Rubis, Marion, additional, Poizat, Flora, additional, Giovannini, Marc, additional, Caillol, Fabrice, additional, and Rochigneux, Philippe, additional

Published
2023
Full Text
View/download PDF

19. Mass cytometry reveals classical monocytes, NK cells and ICOS(+) CD4(+) T cells associated with pembrolizumab efficacy in lung cancer patients

Author

Rochigneux, Philippe, Lisberg, Aaron, Garcia, Alejandro, Granjeaud, Samuel, Madroszyk, Anne, Fattori, Stephane, Gonçalves, Anthony, Devillier, Raynier, Maby, Pauline, Salem, Nassim, Gorvel, Laurent, Chanez, Brice, Gukasyan, Jaklin, Carroll, James, Goldman, Jonathan, Chretien, Anne Sophie, Olive, Daniel, and Garon, Edward B.

Subjects
CD4-Positive T-Lymphocytes, Killer Cells, Natural, Inducible T-Cell Co-Stimulator Protein, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Humans, Article, Monocytes
Abstract

PURPOSE: Immune checkpoint inhibitors (ICI) have revolutionized the treatment of non-small cell lung cancer (NSCLC), but predictive biomarkers of their efficacy are imperfect. The primary objective is to evaluate circulating immune predictors of pembrolizumab efficacy in advanced NSCLC patients. EXPERIMENTAL DESIGN: We use high-dimensional mass cytometry (CyTOF) in baseline blood samples of advanced NSCLC patients treated with pembrolizumab. CyTOF data are analyzed by machine-learning algorithms (Citrus, tSNE) and confirmed by manual gating followed by principal component analysis (BGA). RESULTS: We analyze 27 patients from the seminal KEYNOTE-001 study (median follow-up of 60.6 months). We demonstrate that blood baseline frequencies of classical monocytes, NK cells and ICOS(+) CD4(+) T cells are significantly associated with improved objective response rates, progression-free survival and overall survival (OS). Additionally, we report that a baseline immune peripheral score combining these three populations strongly predicts pembrolizumab efficacy (OS: HR=0.25 95%CI=0.12–0.51, p

Published
2022

20. Impact of fiducial markers placement on the delineation of target volumes in radiation therapy for oesophageal cancer: FIDUCOR study

Author

Rochigneux, Philippe, primary, Tyran, Marguerite, additional, Autret, Aurélie, additional, Lopez Almeida, Leonor, additional, Guiramand, Jérôme, additional, Ferre, Marjorie, additional, Chanez, Brice, additional, Mitry, Emmanuel, additional, Ratone, Jean Philippe, additional, Giovannini, Marc, additional, Tallet, Agnès, additional, Moureau-Zabotto, Laurence, additional, and Caillol, Fabrice, additional

Published
2022
Full Text
View/download PDF

22. Mass Cytometry Reveals Classical Monocytes, NK Cells, and ICOS+ CD4+ T Cells Associated with Pembrolizumab Efficacy in Patients with Lung Cancer

Author

Rochigneux, Philippe, primary, Lisberg, Aaron, additional, Garcia, Alejandro, additional, Granjeaud, Samuel, additional, Madroszyk, Anne, additional, Fattori, Stéphane, additional, Gonçalves, Anthony, additional, Devillier, Raynier, additional, Maby, Pauline, additional, Salem, Nassim, additional, Gorvel, Laurent, additional, Chanez, Brice, additional, Gukasyan, Jaklin, additional, Carroll, James, additional, Goldman, Jonathan, additional, Chretien, Anne Sophie, additional, Olive, Daniel, additional, and Garon, Edward B., additional

Published
2022
Full Text
View/download PDF

23. Do we need postoperative chemotherapy after preoperative FOLFIRINOX in resected borderline or locally advanced pancreatic cancer? A retrospective analysis.

Author

Mari, Roxane, primary, Garnier, Jonathan, additional, Lapeyre-Prost, Alexandra, additional, Rochigneux, Philippe, additional, Dahel, Yanis, additional, Caillol, Fabrice, additional, Giovannini, Marc, additional, Turrini, Olivier, additional, Mitry, Emmanuel, additional, and Chanez, Brice, additional

Published
2022
Full Text
View/download PDF

24. Dysthyroidism during immune checkpoint inhibitors is associated with improved overall survival in solid tumors: Data-mining of 1,382 electronic patient records.

Author

Beaufils, Mathilde, primary, Amodru, Vincent, additional, Tejeda, Manuel, additional, Chanez, Brice, additional, Chretien, Anne Sophie, additional, Gravis, Gwenaelle, additional, Madroszyk, Anne, additional, Goncalves, Anthony, additional, Lisberg, Aaron E., additional, Olive, Daniel, additional, Tassy, Louis, additional, Castinetti, Frédéric, additional, and Rochigneux, Philippe, additional

Published
2022
Full Text
View/download PDF

25. 739P Efficacy and safety of maintenance olaparib and bevacizumab (bev) in ovarian cancer (OC) patients (pts) aged ≥65 years (y) from the PAOLA-1/ENGOT-ov25 first-line trial

Author

Sabatier, Renaud, Vicier, Cécile, Garnier, Séverine, Guille, Arnaud, Carbuccia, Nadine, Isambert, Nicolas, Dalenc, Florence, Robert, Marie, Levy, Christelle, Pakradouni, Jihane, Adelaïde, José, Chaffanet, Max, Sfumato, Patrick, Mamessier, Emilie, Bertucci, François, Goncalves, Anthony, Mezni, Essia, Evans, Catherine Karine, Chinot, Olivier, Loschi, Alain, Arnaud, Sylvie, Mellinas, Marie, Bay, Jacques-Olivier, Bouleuc, Carole, Firmin, Nelly, Gandemer, Virginie, Magne, Nicolas, Orbach, Daniel, Penel, Nicolas, Rodrigues, Manuel, Thiery-Vuillemin, Antoine, Wislez, Marie, L’allemain, Gilles, Robert, Jacques, Colombo, Nicoletta, Dubot, Coraline, Lorusso, Domenica, Caceres, M. Valeria, Hasegawa, Kosei, Shapira-Frommer, Ronnie, Tewari, Krishnansu, Salman, Pamela, Hoyos Usta, Edwin, Yañez, Eduardo, Gümüş, Mahmut, Olivera Hurtado de Mendoza, Mivael, Samouëlian, Vanessa, Castonguay, Vincent, Arkhipov, Alexander, Toker, Sarper, Li, Kan, Keefe, Stephen, Monk, Bradley, Oaknin, Ana, Tinker, Anna, Gilbert, Lucy, Mathews, Cara, Brown, Jubilee, Barretina-Ginesta, Maria-Pilar, Moreno, Victor, Gravina, Adriano, Abdeddaim, Cyril, Banerjee, Susana, Guo, Wei, Danaee, Hadi, Im, Ellie, de Nonneville, Alexandre, Zemmour, Christophe, Frank, Sophie, Joly, Florence, Ray-Coquard, Isabelle, Costaz, Hèlène, Classe, Jean-Marc, Floquet, Anne, de La Motte Rouge, Thibault, Colombo, Pierre-Emmanuel, Sauterey, Baptiste, Leblanc, Eric, Pomel, Christophe, Marchal, Frédéric, Barranger, Emmanuel, Savoye, Aude-Marie, Guillemet, Cécile, Petit, Thierry, Pautier, Patricia, Rouzier, Roman, Gladieff, Laurence, Simon, Gaëtane, Courtinard, Coralie, Rousset-Rouviere, Sandrine, Rochigneux, Philippe, Chrétien, Anne-Sophie, Fattori, Stéphane, Gorvel, Laurent, Provansal, Magali, Lambaudie, Eric, Olive, Daniel, Martin, Johan, Guérin, Mathilde, Monneur, Audrey, Tassy, Louis, Tarpin, Carole, Extra, Jean-Marc, Viret, Frédéric, Pierga, Jean-Yves, Curé, Hervé, Abulnaja, Rakan, Bidard, François-Clément, Mari, Roxane, Narducci, Fabrice, Cappiello, Maria-Antonietta, Rousseau, Fréderique, Blache, Guillaume, Birnbaum, Daniel, Cropet, C., Montegut, C., Frindte, J., Cinieri, S., Guerra-Alia, E.M., Bogner, G., Yoshida, H., Vergote, I., Hietanen, S., Largillier, R., Canzler, U., Gratet, A., Marmé, F., Pujade-Lauraine, E., Favier, L., Ray-Coquard, I.L., Department of Medical Oncology, Institut Paoli-Calmettes, 232 Boulevard Sainte Marguerite, 13009 Marseille, France., Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, and Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)

Subjects
Oncology, medicine.medical_specialty, Bevacizumab, business.industry, First line, [SDV.CAN]Life Sciences [q-bio]/Cancer, Hematology, medicine.disease, Olaparib, chemistry.chemical_compound, chemistry, Internal medicine, Medicine, business, Ovarian cancer, medicine.drug
Abstract

International audience; 5548 Background: Ovarian cancer is the leading cause of death by gynecological cancer. Complete surgery remains one of the main prognostic factors. Laparoscopic exploration is mandatory to assess surgical resectability at diagnosis or after neoadjuvant chemotherapy. However, there is no clinical or biological marker that can correctly predict resectability and may be able to avoid a second laparoscopic exploration for initially unresectable diseases. Our aim was to assess circulating tumor DNA (ctDNA) value as a predictive non-invasive marker of evolution towards resectability for patients with epithelial ovarian cancer receiving first-line chemotherapy. Methods: We explored in this work one of the secondary objectives of the CIDOC study (NCT03302884). CIDOC is a multicenter prospective study aiming to explore ctDNA value as early marker of disease relapse after first-line treatment for epithelial ovarian cancer. Patients with mucinous histology or early stages not requiring chemotherapy are excluded. Plasma samples are collected at diagnosis, during neoadjuvant chemotherapy, and during follow-up. After DNA extraction, panel-based next generation sequencing is performed on both tumor samples and germline DNA, and somatic mutations of interest are selected for ctDNA monitoring. ctDNA analyses are conducted using droplet digital PCR (BioRad QX200) by measuring the variant allele fraction (VAF) of previously identified mutations. Results: This intermediary analysis has included 47 patients diagnosed between March 2017 and December 2019. Median age was 69 years old (48 – 84). Most of the patients had advanced disease (89.4% stage FIGO III or IV), serous histology (94.8%), and high grade tumor (92.3%). Most of the patients underwent complete interval cytoreductive surgery (76.3% vs 17.4% complete upfront surgery). Most of the tumors had TP53 mutations (85.1%), following by alterations involving DNA repair genes (38.3%). Median cell-free DNA concentration at baseline was 0.38 ng/µL (0 – 12.8). ctDNA was identified in 92.1% of patients at baseline with a median VAF of 1.84% (0 – 42.52%). ctDNA VAF was correlated to the peritoneal dissemination ( p= 0.039) assessed with the peritoneal cancer index. ctDNA clearance after preoperative chemotherapy tended to be correlated to achievement of complete interval surgery for patients receiving neoadjuvant chemotherapy ( p= 0.108). Conclusions: ctDNA may be a promising non-invasive marker to assess peritoneal cancer spreading and to predict surgical resectability after neoadjuvant chemotherapy. If confirmed in larger populations, this may enable to avoid additional surgical explorations for patients who remain ctDNA positive after chemotherapy. Clinical trial information: NCT03302884.

Published
2021
Full Text
View/download PDF

27. Immune checkpoint inhibitor induced thyroid dysfunction is a frequent event post-treatment in NSCLC

Author

Zhou, Nanruoyi, primary, Velez, Maria A, additional, Bachrach, Benjamin, additional, Gukasyan, Jaklin, additional, Fares, Charlene M., additional, Cummings, Amy L., additional, Lind-Lebuffe, Jackson P., additional, Akingbemi, Wisdom O., additional, Li, Debory Y., additional, Brodrick, Paige M., additional, Yessuf, Nawal M., additional, Rettinger, Sarah, additional, Grogan, Tristan, additional, Rochigneux, Philippe, additional, Goldman, Jonathan W., additional, Garon, Edward B., additional, and Lisberg, Aaron, additional

Published
2021
Full Text
View/download PDF

28. Endoscopic Ultrasound-Guided Radiofrequency Ablation as an Future Alternative to Pancreatectomy for Pancreatic Metastases from Renal Cell Carcinoma: A Prospective Study

Author

Chanez, Brice, primary, Caillol, Fabrice, additional, Ratone, Jean-Philippe, additional, Pesenti, Christian, additional, Rochigneux, Philippe, additional, Pignot, Géraldine, additional, Thomassin, Jeanne, additional, Brunelle, Serge, additional, Walz, Jochen, additional, Salem, Naji, additional, Giovannini, Marc, additional, and Gravis, Gwenaelle, additional

Published
2021
Full Text
View/download PDF

31. Quantification of Immune Variables from Liquid Biopsy in Breast Cancer Patients Links Vδ2+ γδ T Cell Alterations with Lymph Node Invasion

Author

Fattori, Stéphane, primary, Gorvel, Laurent, additional, Granjeaud, Samuel, additional, Rochigneux, Philippe, additional, Rouvière, Marie-Sarah, additional, Ben Amara, Amira, additional, Boucherit, Nicolas, additional, Paul, Magali, additional, Dauplat, Marie Mélanie, additional, Thomassin-Piana, Jeanne, additional, Paciencia-Gros, Maria, additional, Avenin, Morgan, additional, Pakradouni, Jihane, additional, Barrou, Julien, additional, Charafe-Jauffret, Emmanuelle, additional, Houvenaeghel, Gilles, additional, Lambaudie, Eric, additional, Bertucci, François, additional, Goncalves, Anthony, additional, Tarpin, Carole, additional, Nunès, Jacques A., additional, Devillier, Raynier, additional, Chretien, Anne-Sophie, additional, and Olive, Daniel, additional

Published
2021
Full Text
View/download PDF

33. High-dimensional mass cytometry analysis of NK cell alterations in Acute Myeloid Leukemia identifies a subgroup with adverse clinical outcome

Author

Chretien, Anne-Sophie, primary, Devillier, Raynier, additional, Granjeaud, Samuel, additional, Cordier, Charlotte, additional, Demerle, Clemence, additional, Salem, Nassim, additional, Wlosik, Julia, additional, Orlanducci, Florence, additional, Gregori, Emilie, additional, Paul, Magali, additional, Rochigneux, Philippe, additional, Pagliardini, Thomas, additional, Morey, Mathieu, additional, Fauriat, Cyril, additional, Dulphy, Nicolas, additional, Toubert, Antoine, additional, Luche, Herve, additional, Malissen, Marie, additional, Blaise, Didier, additional, Nunès, Jacques A., additional, Vey, Norbert, additional, and Olive, Daniel, additional

Published
2020
Full Text
View/download PDF

37. Soluble BTN2A1 as a potential predictive biomarker of immune checkpoint inhibitor efficacy in advanced non-small cell lung cancer (NSCLC).

Author

Rochigneux, Philippe, primary, Chretien, Anne Sophie, additional, Rossille, Delphine, additional, Chanez, Brice, additional, Billon, Emilien, additional, Fattori, Stephane, additional, Corre, Romain, additional, Pakradouni, Jihane, additional, Goncalves, Anthony, additional, Fest, Thierry, additional, Madroszyk, Anne, additional, and Olive, Daniel, additional

Published
2020
Full Text
View/download PDF

38. Timing of palliative care needs reporting and aggressiveness of care near the end of life in metastatic lung cancer: A national registry-based study

Author

Goldwasser, François, Vinant, Pascale, Aubry, Régis, Rochigneux, Philippe, Beaussant, Yvan, Huillard, Olivier, Morin, Lucas, AP-HP - Hôpital Cochin Broca Hôtel Dieu [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Aging Research Center [Karolinska Institutet] (ARC ), Stockholm University-Karolinska Institutet [Stockholm], and ROCHIGNEUX, Philippe

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2018
Full Text
View/download PDF

39. Mortality of Patients with Cancer Presenting with Symptoms of COVID-19 With vs Without Detectable SARS-CoV-2: A Nationwide Prospective Cohort Study

Author

Assaad, Souad, primary, Zrounba, Philippe, additional, Cropet, Claire, additional, Faucher, Charlotte, additional, Gachot, Bertrand, additional, Simonet-Lamm, Anne Laure, additional, Lepretre, Stéphane, additional, Vanjak, Dominique, additional, Pernot, Simon, additional, Chergui, Fadila, additional, Stefani, Laetitia, additional, Provencal, Jocelyne, additional, Le Bourgeois, Thibault, additional, Durando, Xavier, additional, Péron, Julien, additional, Schott, Roland, additional, Carbonnelle, Guillaume, additional, Briere, Magali, additional, Belgadi, Blaha, additional, Debreuve, Adeline, additional, Hamon, Marianne, additional, Dramais, Dominique, additional, Rochigneux, Philippe, additional, Brac De La Perriere, Clemence, additional, Campillo-Gimenez, Boris, additional, Gautier, Julien, additional, Febvey-Combes, Olivia, additional, Pérol, David, additional, and Blay, Jean-Yves, additional

Published
2020
Full Text
View/download PDF

40. Dynamic of systemic immunity and its impact on tumor recurrence after radiofrequency ablation of hepatocellular carcinoma

Author

Rochigneux, Philippe, primary, Nault, Jean-Charles, additional, Mallet, Françoise, additional, Chretien, Anne-Sophie, additional, Barget, Nathalie, additional, Garcia, Alejandro J., additional, Del Pozo, Lucie, additional, Bourcier, Valérie, additional, Blaise, Lorraine, additional, Grando-Lemaire, Véronique, additional, N’Kontchou, Gisèle, additional, Nahon, Pierre, additional, Seror, Olivier, additional, Ziol, Marianne, additional, Ganne-Carrié, Nathalie, additional, and Olive, Daniel, additional

Published
2019
Full Text
View/download PDF

41. Acute myositis

Author

Rochigneux, Philippe, Schleinitz, Nicolas, Ebbo, Mikael, Aymonier, Marie, Pourroy, Bertrand, Boissier, Romain, Salas, Sébastien, Deville, Jean-Laurent, Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), University of California [Los Angeles] (UCLA), University of California (UC), Département de médecine interne, Hôpital de la Timone, APHM, Marseille France, Oncopharma, Hôpital de la Timone [CHU - APHM] (TIMONE), Chirurgie urologique et transplantation rénale [Hôpital de la Conception - APHM], Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), Vascular research center of Marseille (VRCM), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Institut National de la Recherche Agronomique (INRA)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d’Oncologie Médicale [Hôpital de la Timone - APHM], and Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE)

Subjects
[SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2018
Full Text
View/download PDF

46. Hospital end-of-life care in haematological malignancies

Author

Beaussant, Yvan, Daguindau, Etienne, Chauchet, Adrien, Rochigneux, Philippe, Tournigand, Christophe, Aubry, Régis, Morin, Lucas, Beaussant, Yvan, Daguindau, Etienne, Chauchet, Adrien, Rochigneux, Philippe, Tournigand, Christophe, Aubry, Régis, and Morin, Lucas

Abstract

Objective To investigate patterns of care during the last months of life of hospitalised patients who died from different haematological malignancies. Methods Nationwide register-based study, including all hospitalised adults >= 20 years who died from haematological malignancies in France in 2010-2013. Outcomes included use of invasive cancer treatments and referral to palliative care. Percentages are adjusted for sex and age using direct standardisation. Results Of 46 629 inpatients who died with haematological malignancies, 24.5% received chemotherapy during the last month before death, 48.5% received blood transfusion, 12.3% were under invasive ventilation and 18.1% died in intensive care units. We found important variations between haematological malignancies. The use of chemotherapy during the last month of life varied from 8.6% among patients with chronic myeloid leukaemia up to 30.1% among those with non-Hodgkin's lymphoma (P<0.001). Invasive ventilation was used in 10.2% of patients with acute leukaemia but in 19.0% of patients with Hodgkin's lymphoma (P<0.001). Palliative status was reported 30 days before death in only 14.8% of patients, and at time of death in 46.9% of cases. Overall, 5.5% of haematology patients died in palliative care units. Conclusion A high proportion of patients who died from haematological malignancies receive specific treatments near the end of life. There is a need for a better and earlier integration of the palliative care approach in the standard practice of haematology. However, substantial variation according to the type of haematological malignancy suggests that the patients should not be considered as one homogeneous group. Implementation of palliative care should account for differences across haematological malignancies.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results